Vanderbilt-Ingram Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vanderbilt-Ingram Cancer Center sits in the top decile of US sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count).
Vanderbilt-Ingram Cancer Center: 189 sponsored US clinical trials, 28 recruiting.
Vanderbilt-Ingram Cancer Center sponsors 189 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 87 completed. 7 of these trials are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.
Top-decile sponsor footprint
Vanderbilt-Ingram Cancer Center ranks in the top decile of sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
87 of 152 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
189 total, page 2 of 4
Yoga Intervention in Supporting Children With Cancer and Their Parents During Chemotherapy Infusion
NCT04034914
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
NCT03962647
Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents
NCT03765099
Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer
NCT03607682
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
NCT03583086
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
NCT03566485
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
NCT03558750
Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer
NCT02937402
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
NCT03179761
Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy
NCT03267381
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
NCT03206203
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
NCT03263429
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
NCT03238196
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
NCT03238248
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
NCT03054038
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
NCT03000179
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
NCT02869633
Hatha Yoga in Breast Cancer Survivors
NCT02923037
Visually Enhanced Education About Prostate Cancer
NCT02846870
Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
NCT02676752
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
NCT02860039
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
NCT02672475
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
NCT02658487
Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis
NCT02677883
PCRC-Supported Legacy Intervention in Pediatric Palliative Care
NCT04059393
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
NCT02493530
Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy
NCT02480114
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
NCT02685631
18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
NCT02448225
Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients
NCT02412241
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
NCT02457910
Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers
NCT02440737
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
NCT02359851
18F-FES PET/CT in Imaging Patients With Desmoid Tumors
NCT02374931
Quantitative MRI in Assessing Disease in Patients With Brain Tumors
NCT02269111
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
NCT02296112
Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy
NCT02324881
Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant
NCT02240381
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
NCT02151539
Programs to Support You During Chemotherapy (Pro-You)
NCT02148406
Home-Based Lymphedema Care Program (HBLCP) in Improving Lymphedema Self-Care in Head and Neck Cancer Survivors
NCT02170272
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
NCT02057874
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
NCT01918306
Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors
NCT01951664
A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
NCT01891747
ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients
NCT01901367
Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
NCT01882231
Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer
NCT01938651
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
NCT01701037
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
NCT01707823
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 51 |
| Phase 3 | 4 |
| Phase 4 | 3 |
What is open in the Vanderbilt-Ingram Cancer Center pipeline
28 recruiting of 189 indexed (15% open); 87 completed (46%).
Phase mix: 7 late (III/IV) vs 97 early (I/II) (early-phase heavy).
Top condition: Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vanderbilt-Ingram Cancer Center: open-pipeline peers nationwide
Peers matched on 189 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Vanderbilt-Ingram Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 189 trials (± recruiting share)
- Nationwide Children's Hospital · 188 trials · 15% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- Arizona State University · 187 trials · 15% recruiting
- Johns Hopkins Bloomberg School of Public Health · 187 trials · 14% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- University of Rochester · 15% recruiting · 636 trials
- Loma Linda University · 15% recruiting · 237 trials
- University of Washington · 15% recruiting · 1,048 trials
Related
What to do with this Vanderbilt-Ingram Cancer Center page
189 registered trials is a research-attention snapshot, not an endorsement of Vanderbilt-Ingram Cancer Center or any single study.
- 28 of Vanderbilt-Ingram Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer is the condition Vanderbilt-Ingram Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vanderbilt-Ingram Cancer Center pipeline card: 189 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.